Podcasts about Drug development

Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a professor at the Oklahoma Medical Research Foundation, explains why physiology remains central to biomedical innovation. Bodine details how physiology strengthens biotech and pharmaceutical research by clarifying how therapies behave in complex biological systems, identifying unintended effects and supporting stronger regulatory narratives. She also examines the expanding role of physiology in wearable technology, remote patient monitoring and artificial intelligence, where biological context is essential to turning large data sets into clinically meaningful insights. The episode also highlights the society’s campaign, “Physiology: The Science Life Depends On,” aimed at elevating awareness of foundational science amid funding uncertainty. For executives, investors and health care leaders seeking sustainable innovation and patient impact, this discussion underscores a clear message: Breakthroughs depend on physiology. Listen to the full interview.See omnystudio.com/listener for privacy information.

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of 10X Growth Strategies, host Arthi Vijayaraghavan sits down with Lakshmi Nair — drug development scientist and genetic engineering researcher — to unpack the science, promise, and responsibility behind CRISPR and gene editing. Drawing from her journey across academia and biomedical research, Lakshmi explains how CRISPR transformed genetic engineering from slow, uncertain experimentation into precise DNA editing — and why that leap could reshape medicine, cancer treatment, and hereditary disease forever. From transgenic models and drug development to the realities of scientific failure and perseverance, the conversation reveals what modern biomedical innovation truly looks like behind the scenes. The episode explores the ethical frontier of gene editing — germline modification, designer traits, disability vs identity, and who gets to decide what should be “fixed” in humans. The discussion also connects CRISPR with AI-driven research, data-intensive clinical trials, and the global scientific ecosystem that turns basic research into life-saving therapies. From biohacking and scientific curiosity to regulation, responsibility, and the future of humanity, this is a thoughtful, deeply grounded conversation on what it means to hold the power to rewrite life itself. A fascinating listen for technologists, policymakers, investors, and anyone curious about where biology, AI, and human evolution intersect. ⸻ 00:00 – Introduction & Lakshmi's Background 02:00 – Why CRISPR Changed Genetic Engineering 06:00 – Scientific Journeys, Curiosity & Upbringing 12:00 – CRISPR Explained for Non-Biologists 18:30 – Medical Applications: Cancer & Genetic Disease 23:30 – Scientific Collaboration & Peer Review 26:30 – Biohacking & Democratizing Biology 30:00 – Gene Editing Ethics & Germline Debate 36:00 – Identity, Disability & Human Choice 40:00 – From Lab Research to Drug Development 45:00 – AI in Clinical Trials & Biomedical Data 50:00 – Future of Gene Editing & Responsibility 54:00 – Closing Reflections

Send a textIn this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR's Healthcare Research Analyst, speak with Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY). The conversation explores Decoy's innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce explains how Decoy is navigating the modern era of drug development with a cost‑effective, highly efficient strategy that positions the company as a disruptive force in biotech. Central to this approach is Decoy' proprietary peptide‑synthesis technology and rapid design‑build‑test cycle, powered by machine learning. He also underscores the importance of Decoy's strategic partnerships with the Gates Foundation, Google, and NVIDIA in advancing its platform and accelerating development.

Dr Lauren Colenso-Semple is back to tackle a series of current trends, narratives, and pseudoscientific claims in fitness and wellness, including:-Is there any quality human research on “wellness peptides”-What are wellness peptides-Why are they becoming more popular-Is there any evidence to suggest that muscle building is any different for women than men-Is there any evidence that birth control affects muscle growth-Is there any difference in protein timing needs for muscle growth in women-Are there notable differences in muscle fibre type between men and women-Is there any association between testosterone levels and lean mass and strength in women-Does menopause accelerate muscle loss-Is creatine as potent as it's currently hyped-Is there any evidence to support cycle syncing-Why is messaging around unique physiological differences so appealing to women-Why are some fitness and wellness “professionals” incentivized to brand around differences in men's and women's training physiology-Are there differences in injury risks across the phases of menstrual cycles-Do vibration plates have any benefits-Is calling out female creators for spreading misinformation by other women “mean girl behaviour”-And much moreIG: @drlaurencs1CHAPTERS01:00 What Are Wellness Peptides and Why They're Trending02:00 How Peptides Work in the Body03:00 Drug Development and Approval Process04:00 Unapproved Peptides in the Wellness Market07:00 Biological Risks and Tumor Concerns08:00 Limited Human Data and Research Quality09:00 Placebo Effects and Pain Resolution10:00 Drug Approval vs Evidence Reality11:00 Placebo Surgery Example and Mind-Body Effects12:00 The “Wild West” of Peptide Research13:00 Manufacturing and Dosing Risks14:00 Why Peptides Became Popular15:00 Normalization of Injectables and “Natural” Marketing20:00 Branding Differences Between Approved Drugs and Peptides24:00 Historical Drug Regulation Context25:00 Are Muscle Gains Different Between Men and Women?26:00 Molecular and Physiological Similarities Between Sexes27:00 Muscle Fiber Type Complexity30:00 Genetics vs Training Adaptation33:00 Athlete Caliber vs Sex Differences37:00 Creatine Performance Effects38:00 Creatine and Clinical Populations39:00 High Dose Creatine Considerations42:00 Testosterone Myths and Hypertrophy43:00 Menopause and Muscle Loss45:00 Measuring Testosterone and Lab Variability46:00 PCOS and Testosterone Levels47:00 Research Gaps in PCOS and Performance48:00 Menstrual Cycle Strength Research Discussion51:00 Why Cycle Syncing Messaging Is Appealing52:00 Marketing Incentives and Female Targeting53:00 Diet Culture Parallel and Behavior Change54:00 Individualization vs Simple Prescriptions55:00 Age vs Training Factors That Actually Matter58:00 Vibration Plates — Claims vs Evidence59:00 Exercise vs Passive Modalities01:01:00 Injury Risk Across Menstrual Cycle PhasesSUPPORT THE SHOWIf this episode helped you cut through confusion in fitness and wellness claims, you can support the show by:• Subscribing and checking out more episodes• Sharing it on your social media (tag me — I'll respond)• Sending it to a friend who's overwhelmed by conflicting adviceFOLLOW ANDREW COATESInstagram: @andrewcoatesfitnesshttps://www.andrewcoatesfitness.comPARTNERS AND RESOURCESRP Strength App (use code COATESRP)https://www.rpstrength.com/coatesJust Bite Me Meals (use code ANDREWCOATESFITNESS for 10% off)https://justbitememeals.comMacrosFirst – FREE Premium TrialDownload MacrosFirst and during setup you'll be asked “How did you hear about us?”Type in: ANDREWKNKG Bags (15% off)https://www.knkg.com/Andrew59676Versa Gripps (discount link)https://www.versagripps.com/andrewcoatesTRAINHEROIC – FREE 90-Day TRIAL (2 steps)Go to https://www.trainheroic.com/liftfreeReply to the email you receive (or email trials@trainheroic.com) and let them know Andrew sent you

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

#ThisMorning | The Use of #AI in the #Drug Development #Process | Andrew R. Snyder, PhD., Early-Stage Biotech Scientist | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode, Dr. Kahina Lang, Executive Director and Head of Next Gen Drug Delivery at Merck Group, discusses her pioneering work developing targeted mRNA delivery systems using lipid nanoparticle (LNP) technology. She shares insights on building an internal startup within the world's oldest pharmaceutical corporation, the technical innovations enabling precision medicine, and the future of cell and gene therapies. Tune in for an insightful conversation on how entrepreneurial leadership, digital-first research approaches, and open-innovation models are accelerating breakthrough therapeutics from the lab to the clinic.

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhanFollow Jorge Conde on X: https://x.com/JorgeCondeBio  Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send a textDr. Raza Bokhari, MD ( https://www.razabokhari.com/ ) is the Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd. ( https://medicuspharma.com/ ), a precision-guided biotechnology company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets designed to transform the standard of care.A physician turned serial entrepreneur, Dr. Bokhari has built a distinguished career identifying, aggregating, and advancing life sciences, healthcare services, and pharmaceutical R&D companies. He is also the Managing Partner of RBx Capital, LP, an investment fund dedicated to biotech and life sciences innovation.Previously, Dr. Bokhari served as Executive Chairman and CEO of FSD Pharma, where he led a strategic transformation of the company from medicinal cannabis into a clinical-stage pharmaceutical R&D organization. Under his leadership, the company achieved a NASDAQ listing in January 2020 and raised nearly $100 million in institutional capital to support growth and expansion.Dr. Bokhari earned his Doctor of Medicine degree from Rawalpindi Medical College at the University of Punjab and holds an Executive MBA from Temple University's Fox School of Business.Beyond his corporate leadership, Dr. Bokhari is Vice Chairman of the World Affairs Council of Philadelphia. He previously served on the Board of Temple University's Fox School of Business as Chairman of the Executive Advisory Committee, and as a Trustee of both The Franklin Institute and the Foreign Policy Research Institute.Through his family foundation, Dr. Bokhari is deeply committed to philanthropy and community engagement. In recognition of a $1 million gift to Temple University, the Fox School named its Innovation & Entrepreneurship Institute Suite in his honor. In 2018, he was named a Centennial Honoree by the Fox School — recognized among a select group of entrepreneurs, visionaries, and disruptors who have shaped the institution and the broader business world since 1918.#Biotech  #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #MedicusPharma #Phase2Biotech #BiotechStrategy #DeRiskThenPartner #CapitalEfficient #Investing #PharmaInvesting #PrecisionBiotech #OncologyInnovation #DrugRepurposing #MedicalInnovation #HealthcareStrategy #ClinicalDevelopment #BiotechBusinessModelSupport the show

“I do not believe we should be testing to test. We have to know, is this test going to change management and is it going to make a difference,” says pediatric allergist-immunologist Dr. Zachary Rubin. His knack for providing that sort of straightforward guidance explains why Dr. Rubin has become a trusted voice on allergies, asthma, and vaccines for his millions of followers on social media platforms. It's also why we couldn't ask for a better guide for our discussion on the rise in allergies, asthma, and immune-related conditions in children, and how families can navigate the quickly evolving science and rampant misinformation in the space. On this episode of Raise the Line, we also preview Dr. Rubin's new book, All About Allergies, in which he breaks down dozens of conditions and diseases, offering clear explanations and practical treatment options for families. Join host Lindsey Smith for this super informative conversation in which Dr. Rubin shares his thoughts on a wide range of topics including: What's behind the rise in allergic and immune-related conditions.Tips for managing misinformation, myths and misunderstandings. How digital platforms can be leveraged to strengthen public health.How to build back public trust in medicine.Mentioned in this episode:All About Allergies bookBench to Bedside PodcastInstagramTikTokYouTube Channel If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

For decades, biology treated the human genome as a tidy instruction manual—genes neatly encoding proteins, surrounded by vast stretches of supposedly irrelevant DNA. As sequencing and molecular tools advanced, that picture fractured: scientists uncovered transposable elements, viral remnants, regulatory RNAs—and even unexpected, tiny non-canonical proteins, often called the “dark proteome.” Today, we know that much of this presumed “junk” DNA is biochemically active under specific conditions, forming an interconnected network of regulatory elements, mobile sequences, non-coding RNAs, and largely uncharacterized proteins. Some scientists believe this dark genomic layer acts as an adaptive reserve, helping genomes respond to stress, disease, and environmental change. In this episode Andreas Horchler and Louise von Stechow have a fascinating discussion with Dr. Sudhakaran Prabakaran, Associate Teaching Professor at Northeastern University, CEO of biotech NonExomics, and author of the upcoming book Eclipsed Horizons, which explores the dark genome, the proteome, evolution, and speculative futures for both humanity and the planet. Find Dr. Sudhakaran Prabakaran https://www.linkedin.com/in/sudhakaranprabakaran/ Find the Eclipsed Horizons https://sites.google.com/view/sudhakaranprabakaran/book Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image Unsplash via NASA Further Reading on the dark genome, proteome and beyond https://pubmed.ncbi.nlm.nih.gov/5065367/ 2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2998295/ 3. https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project 4. https://www.nature.com/articles/538275a 5. https://www.nature.com/articles/512009e 6. https://pubmed.ncbi.nlm.nih.gov/7366731/ 7. https://pubmed.ncbi.nlm.nih.gov/15496913/ 8. https://www.sciencedirect.com/science/article/pii/S0960982212011542 9. https://plato.stanford.edu/entries/genomics/encode-project.html 10. https://www.researchgate.net/publication/269899103_Junk_or_functional_DNA_ENCODE_and_the_function_controversy 11. https://pubmed.ncbi.nlm.nih.gov/19213877/ 12. https://www.nature.com/articles/520615a 13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311765/ 14. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.202100211 15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12701996/ 16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9757701/ 17. https://www.nature.com/articles/ncomms6429 18. https://pubmed.ncbi.nlm.nih.gov/32139545/ 19. https://pubmed.ncbi.nlm.nih.gov/38176414/ 20. https://panspermia.org/mcclintocknrg2023.pdf 21. https://www.pnas.org/doi/10.1073/pnas.1912725116

Most biotech breakthroughs don't fail in the lab.They fail when science meets manufacturing reality.And by the time this bottleneck appears, tens of millions are already sunk.This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions.While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost.In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned.Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact.As he puts it:(00:28:59) “In biotech, courageous decisions often look wrong—until years later.”This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time.What You'll Learn in This Episode1️⃣ Why biologics often fail late—after science already worked2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck3️⃣ How Eleva approaches risk when others walk away4️⃣ Why courage, not optimization, drives breakthrough biotech decisions5️⃣ How AI supports discovery—without replacing human judgment6️⃣ What Europe gets right—and still gets wrong—about scaling biotech

Andrew Beck, MD, PhD is the Co-founder and CEO of PathAI, where he and his team are developing AI tools to improve the precision of pathology and the efficacy of drug development for diagnosis of cancer and also many other complex diseases.Before founding PathAI, Andrew was an Associate Professor at Harvard Medical School, where his research focused on the application of machine learning to cancer pathology. He earned his MD from Brown University and his PhD in Biomedical Informatics from Stanford University, where he pioneered some of the first computational models used to predict patient outcomes in oncology.Time stamps of the conversation:00:00:00 Highlights00:01:28 Introduction00:02:18 Entrypoint in AI00:07:02 Background in Medicine and Bioinformatics 00:10:00 Leap from academia to entrepreneurship00:16:20 Translating AI developments to Pathology00:21:15 Specialist vs Generalist AI models in medicine00:24:15 What sets PathAI apart?00:26:32 AI adoption medicine00:34:25 Usage of AI tools in clinical workflows, example MASH00:40:10 AI in Dermatopathology00:42:15 AI for biomarker discovery00:47:05 Will AI models replace pathologists?00:52:28 Avoiding over-reliance on AI00:57:40 Is AI living unto the hype?01:01:00 Challenges in clinical trials 01:05:12 AI reaching patients directly01:09:50 Working at intersection of AI & Healthcare01:15:30 Pitfalls to learn fromMore about PathAI: https://www.pathai.com/and Andy: https://www.pathai.com/about-us/andy-beckAbout the Host:Jay is a Machine Learning Engineer III at PathAI working on improving AI for medical diagnosis and prognosis. Linkedin: https://www.linkedin.com/in/shahjay22/Twitter: https://twitter.com/jaygshah22Homepage: https://jaygshah.github.io/ for any queries.Stay tuned for upcoming webinars!***Disclaimer: The information in this video represents the views and opinions of the speaker and does not necessarily represent the views or opinions of any institution. It does not constitute an endorsement by any Institution or its affiliates of such video content.***

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Zhi-Gang She from the State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China. Professor She is also the Deputy Director of the Department of Cardiology, Renmin Hospital of Wuhan University. Professor She is interviewed on the paper "Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD" published in paper copy in Gut in February 2026. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

Send us a textDo Heterogeneous Treatment Effects Exist?For the last 50 years, we've designed cars to be safe...For the 50th-percentile male.Well, that's actually not 100% correct.According to Stanford's report, we introduced "female" crash test dummies in the 1960s, but...They were just scaled-down versions of male dummies and...Represented the 5th percentile of females in terms of body size and mass (aka the smallest 5% of women in the general population).These dummies also did not take into account female-typical injury tolerance, biomechanics, spinal alignment, and more.But...Does it matter for actual safety?In the episode, we cover:- Do heterogeneous treatment effects (different effects in different contexts) exist?- If so, can we actually detect them?- Is it more ethical to look for heterogeneous treatment effects or rather look at global averages?Video version available on the Youtube: https://youtu.be/V801RQTBpp4Recorded on Nov 12, 2025 in Malaga, Spain.------------------------------------------------------------------------------------------------------About RichardProfessor Richard Hahn, PhD, is a professor of statistics at Arizona State University (ASU). He develops novel statistical methods for analyzing data arising from the social sciences, including psychology, economics, education, and business. His current focus revolves around causal inference using regression tree models, as well as foundational issues in Bayesian statistics.Connect with Richard:- Richard on LinkedIn: https://www.linkedin.com/in/richard-hahn-a1096050/About StephenStephen Senn, PhD, is a statistician and consultant who specializes in drug development clinical trials. He is a former Group Head at Ciba-Geigy and has taught at the University of Glasgow and University College London (UCL). He is the author of "Statistical Issues in Drug Development," "Crossover Trials in Clinical Research," and "Dicing with Death."Connect with Stephen:- Stephen on LinkedIn: Support the showCausal Bandits PodcastCausal AI || Causal Machine Learning || Causal Inference & DiscoveryWeb: https://causalbanditspodcast.comConnect on LinkedIn: https://www.linkedin.com/in/aleksandermolak/Join Causal Python Weekly: https://causalpython.io The Causal Book: https://amzn.to/3QhsRz4

“Climate change is the biggest health threat of our century, so we need to train clinicians for a future where it will alter disease patterns, the demand on health systems, and how care is delivered,” says Dr. Sandro Demaio, director of the WHO Asia-Pacific Centre for Environment and Health, underscoring the stakes behind the organization's first regionally-focused climate and health strategy. The five-year plan Dr. Demaio is leading aims to help governments in 38 countries with 2.2 billion people manage rising heat, extreme weather, sea-level change, air pollution and food insecurity by adapting health systems, protecting vulnerable populations, and reducing emissions from the healthcare sector itself. In this timely interview with Raise the Line host Michael Carrese, Dr. Demaio draws on his experiences in emergency medicine, global public health, pandemic response and climate policy to argue for an interconnected approach to strengthening systems and preparing a healthcare workforce to meet the heath impacts of growing environmental challenges. This is a great opportunity to learn how climate change is reshaping medicine, public health and the future of care delivery.  Mentioned in this episode: WHO Asia-Pacific Centre for Environment and Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

How can biotech teams move faster (and smarter) from preclinical research to human trials without sacrificing safety or rigor? In this episode, host Elaine Hamm, PhD, sits down with Todd Kilbaugh, MD, Founder of Pharos Biolabs and a physician-scientist specializing in anesthesiology, critical care, and pediatrics. Todd shares his journey from clinical medicine to biotech entrepreneurship and unpacks one of the industry's toughest challenges: why so many promising therapies fail to translate from animal models to humans. Together, they explore how AI, advanced modeling, organoids, and more thoughtful use of non-human primates could reshape preclinical development and reduce costly failures. In this episode, you'll learn: Why the translational gap between animal models and humans remains one of biotech's biggest bottlenecks, and how AI can help close it. How biomarkers, mathematical modeling, and digital twins can improve trial design long before a therapy reaches the clinic. What the future of preclinical development could look like with smarter integration of AI, organoids, and non-human primate studies. Tune in for a wide-ranging conversation on AI-enabled science, better trial prediction, and how biotech can rethink the path from discovery to patients. Links: Connect with Todd Kilbaugh, MD. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Doug Wallace, PhD. Learn more about TBI. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

We have a special episode of Raise the Line on tap today featuring the debut of host Dr. Parsa Mohri, who will now be leading our NextGen Journeys series that highlights the fresh perspectives of learners and early career healthcare professionals around the world on education, medicine, and the future of care. Parsa was himself a NextGen guest in 2024 as a medical student at Acibadem University in Turkey. He's now a general physician working in the Adult Palliative Care Department at Şişli Etfal Research and Training Hospital in Istanbul.  Luckily for us, he's also continuing in his role as a Regional Lead for the Osmosis Health Leadership Initiative (OHLI). For his first guest, Parsa reached out to a former colleague in the Osmosis family, Negeen Farsio, who worked with him as a member of OHLI's predecessor organization, the Osmosis Medical Education Fellowship. Negeen is now a graduate student in medical anthropology at Brunel University of London, a degree which she hopes will inform her future work as a clinician. “Medical anthropology is a field that looks at healthcare systems and how human culture shapes the way we view different illnesses, diseases, and treatments and helps you to see the full picture of each patient.” You are sure to enjoy this heartfelt conversation on how Negeen's lived experience as a patient and caregiver have shaped her commitment to mental health and patient advocacy, and how she hopes to marry humanity with medicine in a world that yearns to heal. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

New research is transforming the outlook for cervical and uterine cancers -- two of the most serious gynecologic malignancies worldwide – and we'll be hearing from one of the people shaping that progress, Dr. Mary McCormack, on this episode of Raise the Line. From her perch as the senior clinical oncologist for gynecological cancer at University College London Hospitals, Dr. McCormack has been a driving force in clinical research in the field, most notably as leader of the influential INTERLACE study, which changed global practice in the treatment of locally advanced cervical cancer, a key reason she was named to Time Magazine's 2025 list of the 100 most influential people in health. “In general, the protocol has been well received and it was adopted into the National Comprehensive Cancer Network guidelines which is a really big deal because lots of centers, particularly in South and Central America and Southeast Asia, follow the NCCN's lead.”In this conversation with host Michael Carrese, you'll learn about how Dr. McCormack overcame recruitment and funding challenges, the need for greater access to and affordability of treatments, and what lies ahead for women's cancer treatment worldwide. Mentioned in this episode:INTERLACE Cervical Cancer Trial If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

China has moved from a fast-following biotech market to a source of globally competitive innovation, according to Josh Smiley, president and chief operating officer of Zai Lab. Speaking on The Top Line podcast, Smiley traces the country’s evolution over the past two decades, pointing to regulatory harmonization, expanded national insurance coverage and deepening R&D capabilities as key drivers. He said the most recent wave of Chinese biotechs is no longer focused solely on domestic opportunities but on first- or best-in-class medicines that can compete worldwide, particularly in oncology and immunology. Smiley also details how Zai Lab blends China’s patient access and development speed with global clinical and regulatory standards, a model he says has helped accelerate programs such as Zai’s DLL3-targeted antibody-drug conjugate for small cell lung cancer into late-stage trials. As China-sourced deals now account for a growing share of global biotech partnerships, Smiley argues companies that integrate China early — without treating it as a standalone market — will have a strategic edge. The conversation offers a candid look at what’s next for Zai Lab and why China’s expanding role in drug innovation is likely to reshape the global pipeline for years to come.See omnystudio.com/listener for privacy information.

“The world is a very volatile place, with currently 110 conflicts globally, and yet healthcare staff in the hospitals, even here in London, are not prepared to be the only clinician who can help in a crisis or hostile setting,” says Dr. David Gough, CEO of the David Nott Foundation, which equips providers with the skills and confidence needed to function in war and other extraordinary situations. A former British Army doctor injured in Afghanistan, Gough brings lived experience as well as a background in tech to his current role at the Foundation, which itself is anchored in decades of field work amassed by its namesake, a renowned war surgeon. As Dr. Gough points out to host Lindsey Smith, the cause could be helped by augmenting medical school curricula, but in the meantime, the Foundation is filling the knowledge gap by using prosthetics, virtual reality simulations and cadavers to train a broad swath of health workers including surgeons, anesthetists, and obstetricians. Tune in to this important Raise the Line conversation as Dr. Gough reflects on the strengths and weaknesses of NGOs in doing this work, his plans to expand the Foundation's footprint in the US, and the gratifying feedback he's received from trainees now operating on the frontlines in Ukraine and elsewhere. Mentioned in this episode:David Nott Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Artificial intelligence is rapidly reshaping drug development by accelerating timelines, enabling more complex biologics, and changing how therapies are designed, delivered, and scaled. But as innovation speeds up, manufacturers face new challenges around delivery platforms, regulatory expectations, and operational agility. In this episode of Off Script, we spoke with Anthony Vico, Head of Business Line, US Technology Excellence Center at Stevanato Group, about how the industry is navigating this shift. The conversation explores the evolving role of drug delivery systems, where AI and machine learning are having the most immediate impact, how advanced therapeutic modalities fit into this changing landscape, and what manufacturers must do to remain competitive.

​The Oxford-Harrington Rare Disease Centre represents a transatlantic alliance created to bridge academic research and drug development for rare diseases. Founded in 2019 by the United Kingdom's University of Oxford and the Cleveland-based Harrington Discovery Institute, the center leverages Oxford's world-class rare disease research and Harrington's pharmaceutical-scale expertise to address translational challenges and advance promising therapies for rare diseases lacking approved treatments. We spoke to Matthew Wood, director of the Oxford-Harrington Rare Disease Centre, about the challenges of rare disease drug development, the resources the center brings to address them, and the mechanisms it has established to accelerate therapeutic development.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show

What if the key to curing today's most complex diseases has been hiding in plain sight inside electronic health records all along?In this episode of Straight Out of Health IT, Vish Srivastava, CEO of Century Health, explores how artificial intelligence can unlock the vast potential of real-world healthcare data that has long been trapped inside electronic health records. He explains why traditional clinical trials, although essential, often fail to accurately reflect how treatments perform across diverse, real-world patient populations, and how this gap hinders innovation. Drawing from both his professional journey and the personal experience of losing his grandfather to Alzheimer's, Vish shares what motivates his mission to better understand disease progression and accelerate breakthrough treatments.Vish breaks down what real-world data actually is, why more than 80% of it remains unstructured, and how fragmented EHR systems have made research slow, expensive, and inaccessible. He describes how observational studies and patient registries can take years and cost millions due to manual chart abstraction, and how carefully validated AI can now automate this process, turning clinical notes, PDFs, and imaging data into high-quality research-ready insights. The conversation also highlights how this approach can broaden research beyond historically narrow clinical trial populations.Ultimately, the episode addresses the crucial issues of trust, bias, and patient privacy. Vish discusses how AI can either perpetuate or correct historical biases in healthcare data, why transparency and published validation are essential, and how strict de-identification and governance frameworks protect patient privacy. Together, these advances point toward a future where real-world data fuels faster, more inclusive, and more impactful medical research.Tune in to hear how AI is reshaping clinical research and bringing us closer to treatments that truly work for real patients in the real world!ResourcesConnect with Vish Srivastava on LinkedIn here.Follow Century Health on LinkedIn here and visit their website here.

This episode is a collection of my thoughts on model-informed drug development and where different modeling modalities fit into the development schedule. These are just my opinions and each development program is different.Links discussed in the show:You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

在美國的藥廠臨床部門，建立人脈與跨部門溝通是必不可少的技能。對於剛畢業的新鮮人，或正處於職涯早期，仍在探索方向的工作者而言，這樣的能力更顯關鍵。對於內向的 I 人朋友來說，建立人脈、與人互動或許令人倍感壓力，但這其實並非無法跨越的障礙，而是可以被刻意練習、逐步培養的軟實力！   本集邀請現任 BTBA（波士頓台灣人生技協會）的共會長之一廖怡恩博士。怡恩在去年 S4 EP18 跟我們分享了轉譯醫學與臨床藥物開發的流程與工作趣事，當時怡恩在Novartis藥廠擔任Fellow。經過一年半的歷鍊，怡恩成功在Biomarker Development 部門轉正成為Senior Scientist。節目中怡恩將會跟我們分享他一路以來的心路歷程，包括他身為一位內向者 (Introvert) ，他如何將建立人脈視為可培養的技能，並透過事先準備與策略性規劃，建立良好的交流方式；也分享了他如何在職涯早期探索自己的發展方向，並透過公司內部的人際連結，成功從Fellow轉為正職員工。   節目的最後，我們將邀請另一位 BTBA 共同會長楊志祥一起加入討論，分享他們與 BTBA 的淵源，以及對組織未來一年的規劃與展望。  

On this episode Lara and Vyanka talk to Dr Anish Suri all about the development of new drugs that target the immune system and treat immunological disease. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative events shaping the future of drug development, patient care, and global healthcare strategies.**Johnson & Johnson's Multiple Myeloma Advances** Johnson & Johnson has made significant strides in the treatment of multiple myeloma with their bispecific antibody, Tecvayli. In recent trials, Tecvayli has shown remarkable promise when used in combination therapies as a second-line treatment. This development is noteworthy as it could potentially challenge the dominance of CAR-T cell therapies like J&J's Carvykti by offering a more accessible and less complex alternative. For patients, this means potentially fewer logistical hurdles and a more straightforward therapeutic option, which could drastically improve patient care standards.**Regulatory Scrutiny on RSV Vaccines** Turning to regulatory news, the U.S. FDA has intensified its scrutiny of respiratory syncytial virus (RSV) vaccines developed by pharmaceutical giants such as Merck, AstraZeneca, and Sanofi for infants. This increased oversight follows reports linking some COVID-19 vaccines to adverse effects in children. The FDA's actions highlight the ongoing necessity for vigilant safety monitoring in vaccine development, especially for vulnerable populations like infants. This is a crucial step in ensuring that vaccines designed for our youngest population are both safe and effective.**Eli Lilly's Strategic Moves in Oncology and Beyond** Eli Lilly is making waves in oncology with its BTK inhibitor, Jaypirca. Despite strong phase 3 results that support its use as a first-line treatment for chronic lymphocytic leukemia (CLL), Lilly is focusing on its application as a second-line therapy. This strategic choice reflects an astute understanding of market dynamics and therapeutic niches where Jaypirca can provide substantial benefits despite competition from established first-line treatments. Additionally, Eli Lilly continues to leverage its financial success from its weight loss drug Tirzepatide to position itself as a central player in global pharmaceutical innovation. The company's strategic investments are likely to catalyze advancements across various therapeutic areas, reinforcing its role as a key contributor to medical breakthroughs.**Legislative Impact on Biopharma** In legislative news, the Biosecure Act's incorporation into the U.S. National Defense Authorization Act marks a strategic shift towards tightening regulations on Chinese biopharma entities regarding federal contracts by 2026. This move could have profound implications for international collaborations and competition within biotechnology innovation and drug development sectors. It signals a broader trend of increased scrutiny on foreign entities in sensitive industries like biopharmaceuticals.**China's Healthcare Transformation** China's healthcare landscape is undergoing significant transformation with the inclusion of drugs from companies like Pfizer, Lilly, and J&J into its first private insurance formulary. This development could enhance access to innovative medications within China, potentially improving health outcomes and influencing global pricing strategies in the pharmaceutical industry.**Gamida Cell's Milestone in Cell Therapies** In a major milestone for cell therapies, Gamida Cell has secured a second FDA approval for its stem cell therapy Omisirge. Initially approved to reduce infection risk during hematopoietic stem cell transplantations in blood cancer patients, Omisirge's expanded indication to treat severe aplastic anemia underscores the potential of cell therapies in addressing diverse hematologic conditions.**CSL Seqirus' New Facility in Australia** In Australia, CSL Seqirus has opened a $1 billion facility dedicated to producing cell-baSupport the show

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Dr. Dale: When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.Millions of people worldwide face the devastating impact of cancer, with countless lives lost each year to tumors that no longer respond to existing treatments. Dr. Dale Walker, Co-founder and CEO of The Burlington HC Research Group (BHCRG), is working to change that narrative with her groundbreaking development of a new family of anti-cancer drugs. These drugs have the potential to revolutionize treatment for cancers that have become resistant to current therapies.“We tested our drugs against 15 human cancer cell lines, representative of seven different tissues, and the drug works against all of them,” Dale explained. In the U.S. alone, over 600,000 people die annually from cancer, often because their tumors no longer respond to treatment. Dale's research offers a glimmer of hope for patients and their families.Unlike traditional drug development that focuses on a single compound, Dale and her team have created a family of drugs—called BRG drugs—by combining two FDA-approved ingredients in a novel way. These drugs not only enhance the effectiveness of existing cancer treatments but also demonstrate the ability to kill nearly all cancer cells after a single dose in preclinical studies. “Most anti-cancer agents just slow tumor growth. Ours hit both marks—killing tumor cells at a safe dose level,” she said.With such promising results, Dale and her husband Vernon, who co-leads the research, are pushing forward. However, taking these drugs through the necessary safety and efficacy tests requires significant funding. To accelerate progress, BHCRG is raising capital through a regulated crowdfunding campaign on the FundingHope platform. Crowdfunding offers a faster alternative to traditional funding sources, enabling the Walkers to bypass lengthy government grant timelines.“Crowdfunding is a lifeline. We have family members and friends with cancer. We can't wait years,” Dale shared. For investors, the opportunity to back a potential game-changing cancer therapy is compelling, both for its societal impact and long-term financial potential.Dale's passion and perseverance shine through in her work. Her innovative approach to drug development could save countless lives. Supporting her mission on Funding Hope isn't just an investment in a company—it's an investment in hope.tl;dr:Dale Walker shares her innovative work on new anti-cancer drugs targeting resistant tumors.BHCRG's BRG drugs show promising preclinical results, killing almost all tumor cells with one dose.Dale explains crowdfunding's role in accelerating drug development for life-saving cancer treatments.She discusses perseverance as her superpower, solving challenges by embracing and examining problems.Today's episode highlights how crowdfunding enables investors to support impactful innovations in healthcare.How to Develop Perseverance in Problem-Solving As a SuperpowerDale's superpower is her extraordinary ability to solve complex problems and persevere through challenges. In today's episode, she explained, “When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.” Dale emphasized that problems often contain valuable information that leads to solutions, encouraging others to examine challenges closely rather than avoiding them.After discovering that an FDA-approved drug had antiviral activity, Dale faced a seemingly insurmountable challenge: making the drug work effectively in people. “I thought, I will not be able to solve this problem. It's too hard,” she admitted. Yet, she persevered, combining the drug with another FDA-approved ingredient. This breakthrough created the BRG family of cancer drugs, which kill nearly all cancer cells in preclinical studies after a single dose. Her ability to persist through doubt and difficulty exemplifies her superpower.Tips for Developing Perseverance in Problem-Solving:Acknowledge Your Strengths: Remind yourself that you've solved tough problems before and can do it again.Examine Problems Closely: Instead of avoiding challenges, look for clues within the problem itself to guide solutions.Break Down the Problem: Address each component of the challenge one step at a time.Stay Focused: Resist the urge to pivot too quickly; often, solutions lie in persistence.Find Inspiration: Remember the impact your work can have on others to stay motivated.By following Dale's example and advice, you can make perseverance in problem-solving a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDale M. Walker (she/her):Co-founder, owner, and Chief Executive Officer, The Burlington HC Research Group, Inc. (BHCRG)About The Burlington HC Research Group, Inc. (BHCRG): BHCRG is working to advance a new family of investigational drugs called BRG Therapeutics. Based on pre-clinical studies, two members of this family show potent anticancer activity across human cancer cell lines representing seven different tissues of origin, including lung cancer (four subtypes), prostate cancer (three types), triple-negative breast cancer (two types), ovarian cancer (two types), pancreatic cancer (one type), pleural mesothelioma (two types), and pre-myeloblastic leukemia (one type, tested with a single BRG drug). In tissue-culture models, BRG drugs demonstrate an unusually strong ability to eliminate nearly all cancer cells after a single dose while achieving this result at doses that are non-toxic to normal human cells. Each BRG drug delivers two active ingredients, and the primary component (ingredient #1) also inhibits the replication of viruses spanning all three major viral genome classes—DNA viruses, RNA viruses, and reverse-transcribing/retroviruses—with activity shown in vitro against influenza, COVID-19, HIV, and Ebola and other viruses. Although such breadth is uncommon and has led some observers to believe no drug could achieve these effects, the evidence shows that the human body naturally produces several essential compounds with similarly broad anticancer and antiviral functions; BRG drugs work through analogous biochemical mechanisms but produce stronger effects in controlled laboratory studies. These naturally occurring comparators include N-acetylcysteine, glutathione, and vitamin C (only at pharmacologic doses). Taken together, BRG Therapeutics represents a next-generation, multi-targeted approach designed to overcome one of the central limitations of modern oncology—drug resistance—by restoring normal cellular regulation, reactivating p53, correcting redox imbalance, and neutralizing reactive species to selectively eliminate cancer cells while preserving healthy tissue.Website: bhcrg.comCompany Facebook Page: facebook.com/profile.php?id=61584197824692Other URL: invest.fundinghope.com/offering/brg/detailsBiographical Information: My husband Vernon and I work together as a team, and we have advanced BRG therapeutics to their present state of development by collaboration. We both are veterinarians with advanced training in pathology, so that make us ‘veterinary pathologists'. Vernon also has a PhD in experimental and molecular pathology. What many people do not know is that veterinary pathologists have key roles in drug development and safety testing. Before the discovery of the BRG drugs, most of our work focused on health risks from human exposures to environmental, workplace, or medicinal agents/compounds. We were working with BRG active ingredient #1, which is FDA-approved as the active form of a cell protective drug – that means that it protects normal cells from the damaging effects of radiation and some chemicals. We were testing the ability of this agent to protect normal cells from the deleterious effects of some of the first drugs like AZT developed to treat HIV. We were surprised to learn that this cell protective drug had antiviral activity all on its own. Even though this active ingredient had been around for several decades, no one had ever reported these results before we did. We soon learned why we were the first to make this discovery - the active ingredient of this cell protective drug worked well in tissue culture as an antiviral agent, but antiviral effects were not achieved in living animals. This sent us on a long road figuring out why this was – after all, this agent worked to protect normal cells in living animals and people, so why would it not work as an antiviral agent in the same animals and people? It actually took several years to understand the nature of the problems, and even more time to figure out a solution. That solution was the BRG therapeutics.Vernon and I had little experience studying viruses, and much more experience studying cancer and anticancer drugs, and we knew that this active ingredient had anticancer activity, so we decided to start with testing a BRG drug as an anticancer agent. Our first experiment in a human, pre-myeloblastic leukemia cell line showed us anticancer effects beyond anything that we could have imagined. We were so excited, but we still had a long journey of work and discovery ahead of us. To date we have tested two BRG drugs and they kill cancer cells in all human cancer cell lines tested to date (one drug tested in 15 human cancers, the other tested in 14). A paper summarizing these results was published in 2023.LinkedIn Profile: linkedin.com/in/dale-m-walker-bhcrgPersonal Facebook Profile: facebook.com/profile.php?id=61556212335476Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and SuperGreen Live. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Superpowers for Good Live Pitch, December 11, 2025, at 8:00 PM Eastern / 5:00 PM Pacific, will bring together four mission-driven founders—Fran Maier (BabyQuip), Farooq Zama (CureValue), Andrei Evulet (Jetoptera), and Erin Martin (Pump For Joy)—as they present their companies live to a national audience on e360tv, YouTube, and LinkedIn. Hosted by Devin Thorpe, CEO and Founder of The Super Crowd, Inc., this special broadcast showcases entrepreneurs raising capital to solve real-world problems across family travel, healthcare access, disaster response aviation, and maternal health. Viewers are encouraged to watch the live pitches and then continue the experience by joining the Private Investor Session immediately following the broadcast, where attendees can engage directly with founders, ask deeper questions, and explore their active investment offerings in a focused, off-air environment. Whether you are an active investor or simply interested in the future of mission-driven innovation, this event offers a rare opportunity to witness purpose-driven companies in action and connect with them directly after the show.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on December 16, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, December 17, 2025, at 12:00 PM Eastern, will feature Devin Thorpe, CEO and Founder of The Super Crowd, Inc., leading a session on “Designing a Winning Marketing Strategy for Your Investment Offering.” Drawing on his deep experience in impact crowdfunding and investment storytelling, Devin will break down the essential elements of building a marketing strategy that attracts, engages, and converts potential investors. Participants will learn how to identify and reach the right audience, craft messages that build trust, and develop a promotional plan that supports sustained momentum throughout a raise. Whether you're preparing for your first regulated investment crowdfunding campaign or looking to strengthen an ongoing one, this SuperCrowdHour will provide the insights and practical frameworks you need to elevate your offering and boost investor participation.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.CfPA President-elect's Vision for 2026 with Brian Belley, December 17 at 2:00 PM ET – reserve your spot now!If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

This is the Engineering Culture Podcast, from the people behind InfoQ.com and the QCon conferences. In this podcast, Shane Hastie, Lead Editor for Culture & Methods, spoke to Satish Kothapalli about the transformative impact of AI and vibe coding in life sciences software development, the acceleration of drug development timelines, and the evolving roles of developers in an AI-augmented environment. Read a transcript of this interview: https://bit.ly/3M2E9ZH Subscribe to the Software Architects' Newsletter for your monthly guide to the essential news and experience from industry peers on emerging patterns and technologies: https://www.infoq.com/software-architects-newsletter Upcoming Events: QCon AI New York 2025 (December 16-17, 2025) https://ai.qconferences.com/ QCon London 2026 (March 16-19, 2026) QCon London equips senior engineers, architects, and technical leaders with trusted, practical insights to lead the change in software development. Get real-world solutions and leadership strategies from senior software practitioners defining current trends and solving today's toughest software challenges. https://qconlondon.com/ QCon AI Boston 2026 (June 1-2, 2026) Learn how real teams are accelerating the entire software lifecycle with AI. https://boston.qcon.ai The InfoQ Podcasts: Weekly inspiration to drive innovation and build great teams from senior software leaders. Listen to all our podcasts and read interview transcripts: - The InfoQ Podcast https://www.infoq.com/podcasts/ - Engineering Culture Podcast by InfoQ https://www.infoq.com/podcasts/#engineering_culture - Generally AI: https://www.infoq.com/generally-ai-podcast/ Follow InfoQ: - Mastodon: https://techhub.social/@infoq - X: https://x.com/InfoQ?from=@ - LinkedIn: https://www.linkedin.com/company/infoq/ - Facebook: https://www.facebook.com/InfoQdotcom# - Instagram: https://www.instagram.com/infoqdotcom/?hl=en - Youtube: https://www.youtube.com/infoq - Bluesky: https://bsky.app/profile/infoq.com Write for InfoQ: Learn and share the changes and innovations in professional software development. - Join a community of experts. - Increase your visibility. - Grow your career. https://www.infoq.com/write-for-infoq

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren't yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he's especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Dillan DiNardo, Co-Founder and CEO of Mindstate Design Labs, returns to the Mycopreneur Podcast to share updates on the companies progress as a clinical-stage AI neuroengineering platform and drug development outfit. We explore how Mindstate Design is leveraging artificial intelligence in their drug development process, discuss the origins of the company and it's connection to legendary drug chemist Alexander "Sasha" Shulgin, and cover the evolving landscape of psychedelic drug research and where it could all go from here.Please rate and review wherever you're listening ( : Hosted on Acast. See acast.com/privacy for more information.

Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher's ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Gideon Blumenthal, MD, vice president of Clinical Development Oncology at Merck in Silver Spring, Maryland. Drs Camidge and Blumenthal discussed Dr Blumenthal's experience serving on both sides of the oncology regulatory divide. Though initially leaning toward humanities during his education, he pursued a career in medicine. During medical school, he shifted his focus from neuroscience to oncology due to the field's high unmet need, fascinating drug development pathways, and the intensity of patient interaction. He chose to complete his hematology and oncology fellowship at the National Cancer Institute to immerse himself in translational oncology and drug development. Before joining industry, Dr Blumenthal also spent several years working for the FDA. He started there as a medical officer, focusing on all facets of drug development, from ethics and manufacturing to trial design and biostatistics. He emphasized that success at the FDA involves both approving effective agents and identifying drugs that do not work, maintaining transparency through venues like the public Oncologic Drug Advisory Committee meetings. He used FDA data to conduct independent meta-research, such as analyzing the correlation between response rates and overall survival in lung cancer. His proudest achievement at the FDA was helping to establish the Oncology Center of Excellence, which unified drug development reviews across different centers within the agency. Dr Blumenthal left the FDA in early 2020, seeking to gain direct experience in developing new therapeutics. Joining Merck, he first worked in regulatory affairs, navigating international regulations in addition to US filing procedures, which are typically prioritized in oncology. He later transitioned into clinical development, and currently focuses on new assets as Merck evolves its pipeline beyond pembrolizumab (Keytruda). Dr Blumenthal concluded that he is excited by the future of oncology, anticipating radical changes driven by new modalities and advanced biomarkers like artificial intelligence–driven digital pathology.

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how investigator-initiated trials in Shanghai are rewriting the competitive playbook faster than American founders can file INDs. When the infrastructure that built monoclonal antibodies becomes the commodity threatening to hollow out an entire industry, the only path forward demands inventing medicines that are literally impossible to make without tools that don't exist yet—and they're betting everything on which approach survives. Resources:Follow Jorge on X: https://x.com/JorgeCondeBioFollow Lada on X: https://x.com/ladanuzhnaFollow Elliot on X: https://x.com/ElliotHershbergFollow Erik on X: https://x.com/eriktorenberg Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: https://x.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zListen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYXListen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711Follow our host: https://x.com/eriktorenbergPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.   Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“I realized that rather than talking one-to-one with patients in the exam room, you could talk one-to-many on social media,” says Dr. Kevin Pho, explaining the origins of KevinMD, the highly influential information sharing site he created for physicians, medical students and patients twenty years ago. Since then, KevinMD has become a valuable space for clinicians and patients to share stories and perspectives on topics from burnout and moral injury to technology and trust. In this conversation with Raise the Line host Michael Carrese, Dr. Pho reflects on the dual paths that have defined his career: as a practicing internal medicine physician and as one of healthcare's most trusted online voices. And despite the challenges of doing so, Dr. Pho encourages other medical providers to follow his lead. “Patients are going online, and if physicians are not there, they're going to get information that's perhaps politically-driven or simply inaccurate.”This thoughtful conversation also explores: How social media has reshaped health communicationThe risks and rewards for clinicians of having an online presence Why medical schools should teach negotiating skillsMentioned in this episode:KevinMDEstablishing, Managing and Protecting Your Online Reputation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“We've created this ecosystem where the vast majority of information on social media, particularly in nutrition science, is inaccurate or misleading,” says Dr. Jessica Knurick, a registered dietitian and Ph.D. in nutrition science specializing in chronic disease prevention. As you'll learn on this episode of Raise the Line with host Lindsey Smith, countering that trend has become Dr. Knurick's focus in the past several years, and her talent for translating complex scientific information into practical guidance has attracted a large following on social media. Beyond equipping her audience with the tools to think critically and make informed choices for themselves, she also wants them to make the connection between the generally poor health status of most Americans with public policies on food and health and advocate for more beneficial approaches. “We can create systems that put the most people in the position to succeed versus putting the most people in the position to fail.” Tune in to learn from this trusted voice on nutrition, food policy, and public health as she shares her perspectives on: Strategies for risk reduction and behavior changeWhat can rebuild trust in medical information How you can cut through the noise and spot misinformation onlineMentioned in this episode:Dr. Knurick's WebsiteTikTok ChannelInstagram FeedFacebook Page If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast